About: Jason Novak


Bio: Jason has been a consistent contributor to VectorVest and has a blended interest in technology and finance, which he has written about for over a decade. When he's not demystifying complex financial topics or sharing a quick analysis of hot stocks on a given day, you may find him on the golf course or exploring all that Northern California has to offer.

Posts by Jason Novak:

Volkswagen is Investing Billions into Rivian: Why You Should Invest in RIVN, Too

Posted on: 02 Jul 2024

Boeing Buying Spirit Aerosystems is a Positive Step to Improve Safety, But We Still See Issues With BA

Posted on: 01 Jul 2024

Walgreens Stock Plummets 22% After Disappointing Q3 Results: Why it’s Time to Cut Losses on WBA

Posted on: 28 Jun 2024

Micron Tech Tumbles 6% on Less Than Fantastic Forecast: 3 Reasons It’s STILL Time to Buy MU

Posted on: 27 Jun 2024

FedEx Cost Cuts and Upbeat Outlook Send Shares 14% Higher: 3 Other Reasons to BUY FDX

Posted on: 26 Jun 2024

Analysts are Bullish on IBM, But is it Actually Time to Buy This Stock? 3 Things to Consider First

Posted on: 25 Jun 2024

Should You Buy Chipotle (CMG) Ahead of the 50-for-1 Stock Split? 3 Things to Consider

Posted on: 24 Jun 2024

Top 10 Monthly Dividend Stocks to Hold Forever

Posted on: 23 Jun 2024

Investing in monthly dividend stocks is a great way to earn consistent income to cover ongoing expenses. Or, you could be trying to invest for early retirement hoping to harness the compounding returns dividend stocks have to offer. Whatever the case, you’ve come to the right place. We’re going to unveil the top 10 monthly […]

Pros and Cons of Dividend Stocks

Posted on: 22 Jun 2024

Dividend stocks are one of the top stock investment strategies as they can provide supplemental income for present-day expenses OR be used to build towards long-term wealth goals through a reinvestment strategy.  No matter your goals with investing in dividend stocks, you’re typically going to enjoy much less volatility. We consider blue chip stocks with […]

Sarepta Shoots up 36% on New Drug Breakthrough for DMD: 2 Reasons to Consider Buying SRPT

Posted on: 21 Jun 2024